Growth and Spread of Breast Cancer Linked to Tumor Cells' Expression of a Cartilage Protein
|
By LabMedica International staff writers Posted on 27 Apr 2016 |

Image: High expression of COMP in breast cancer cells, seen here in brown, was associated with poor clinical prognosis for the patient. Cancer cells expressing COMP became more invasive and changed their metabolism, which allowed them to survive better and spread to other organs (Photo courtesy of Dr. Anna Blom, Lund University).
A team of Swedish cancer researchers has identified a protein in breast tumors and surrounding stromal tissue that contributes to the development and spread of the disease.
Investigators at Lund University (Malmö, Sweden) using tissue microarrays derived from two cohorts of patients with breast cancer found that the protein COMP (cartilage oligomeric matrix protein), a soluble pentameric protein expressed in cartilage and involved in collagen organization, was expressed to a varying degree in the tumor cells and surrounding stroma. High levels of COMP in tumor cells correlated, independently of other variables, with poor survival and decreased recurrence-free survival. Normal breast tissue did not express detectable levels of COMP.
The investigators injected MDA-MB-231breast cancer cells that stably expressed COMP into the mammary fat pads of SCID (CB-17/Icr-Prkdcscid/Rj) mice. They reported in the April 11, 2016, online edition of the journal Oncogene that tumors expressing COMP were significantly larger and were more prone to metastasize as compared with control tumors that did not express the protein.
In vitro experiments confirmed that COMP-expressing cells had a more invasive phenotype, which could in part be attributed to an upregulation of the enzyme matrix metalloprotease-9. Microarray analyses of gene expression in tumors formed in vivo showed that COMP expression induced higher expression of genes protecting against endoplasmic reticulum stress. Furthermore, in vitro measurement of cell respiration indicated that COMP-expressing cells appeared to undergo a metabolic switch, that is, a Warburg effect, in which they produced energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells.
Based on these results, the investigators concluded that COMP was a novel biomarker in breast cancer, which contributed to the severity of the disease by metabolic switching and increasing invasiveness and tumor cell viability, leading to reduced survival in animal models and human patients.
"We saw a clear association between high levels of COMP and a worse breast cancer prognosis. With more research, COMP has the potential of becoming an indicator of aggressive breast cancer, and thereby providing early and valuable information before deciding on an appropriate treatment," said senior author Dr. Anna Blom, professor of protein chemistry at Lund University.
Related Links:
Lund University
Investigators at Lund University (Malmö, Sweden) using tissue microarrays derived from two cohorts of patients with breast cancer found that the protein COMP (cartilage oligomeric matrix protein), a soluble pentameric protein expressed in cartilage and involved in collagen organization, was expressed to a varying degree in the tumor cells and surrounding stroma. High levels of COMP in tumor cells correlated, independently of other variables, with poor survival and decreased recurrence-free survival. Normal breast tissue did not express detectable levels of COMP.
The investigators injected MDA-MB-231breast cancer cells that stably expressed COMP into the mammary fat pads of SCID (CB-17/Icr-Prkdcscid/Rj) mice. They reported in the April 11, 2016, online edition of the journal Oncogene that tumors expressing COMP were significantly larger and were more prone to metastasize as compared with control tumors that did not express the protein.
In vitro experiments confirmed that COMP-expressing cells had a more invasive phenotype, which could in part be attributed to an upregulation of the enzyme matrix metalloprotease-9. Microarray analyses of gene expression in tumors formed in vivo showed that COMP expression induced higher expression of genes protecting against endoplasmic reticulum stress. Furthermore, in vitro measurement of cell respiration indicated that COMP-expressing cells appeared to undergo a metabolic switch, that is, a Warburg effect, in which they produced energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells.
Based on these results, the investigators concluded that COMP was a novel biomarker in breast cancer, which contributed to the severity of the disease by metabolic switching and increasing invasiveness and tumor cell viability, leading to reduced survival in animal models and human patients.
"We saw a clear association between high levels of COMP and a worse breast cancer prognosis. With more research, COMP has the potential of becoming an indicator of aggressive breast cancer, and thereby providing early and valuable information before deciding on an appropriate treatment," said senior author Dr. Anna Blom, professor of protein chemistry at Lund University.
Related Links:
Lund University
Latest BioResearch News
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
- Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
- Research Reveals How Some Aplastic Anemia Patients Recover Bone Marrow Function
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
Channels
Clinical Chemistry
view channel
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read more
CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
Specialized care settings frequently evaluate patients aged 50 years and older who present with signs and symptoms of cognitive decline to determine whether amyloid pathology linked to Alzheimer’s disease... Read moreMolecular Diagnostics
view channel
Blood-Based “Ageing Clock” Helps Predict Dementia Risk and Earlier Onset
Dementia imposes a growing health burden, affecting an estimated 982,000 people in the UK, with cases projected to reach 1.4 million by 2040. Earlier identification of those most likely to develop disease... Read more
Blood Test Refines Biopsy Decisions in Prostate Cancer
Prostate biopsy decisions remain challenging, with many men undergoing invasive procedures that ultimately yield negative results. In the U.S., more than a million prostate biopsies are performed each... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








